Investor Relations

Corporate Profile

Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Print Page
Email Alerts
RSS Feeds
Investor Contacts